Anika Therapeutics(US:ANIK)2025-07-30 12:30Financial Performance - Revenue decreased by 8% to $282 million in Q2 2025[9, 11], driven by a 13% decrease in OEM revenue[9, 11] - Commercial Channel revenue was flat[11] - Gross profit decreased due to lower OEM channel revenue and higher manufacturing costs[11] - R&D expenses decreased primarily due to reduced headcount and lower spend associated with product development and regulatory activities[11] - SG&A expenses decreased due to a prior year one-time, non-recurring expense along with cost actions taken in the past year[11] - Adjusted EBITDA was $02 million[9] - Adjusted EPS was $(013)[9] Business Updates - Regenerative Solutions portfolio grew 41% year-over-year[8] - International OA Pain business grew 5% sequentially, but was down 10% year-over-year due to 2024 order timing and temporary production yield issues[8] - Integrity Implant System is exceeding launch expectations and outpacing the market, on pace to more than double in 2025[8] - Hyalofast FastTRACK study did not meet pre-specified co-primary endpoints for KOOS Pain and IKDC Function[6]